Sulzer Medica bid to convert final opt-outs in US implants case
This article was originally published in Clinica
Sulzer Medica last week found that it was not yet out of the woods in its efforts to settle US claims for compensation following problems with its hip and knee implants, when 120 plaintiffs refused to opt in for a share of the $1 billion compensation on offer from the Zurich, Switzerland company. 99.6% of plaintiffs opted for the package by the May 15 deadline, but the laggard 0.4% could present sizeable problems, and perhaps still force Sulzer's US orthopaedic subsidiary into bankruptcy.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.